Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations

NCT02855047 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nīmes as lead sponsor.

NCT NCT02855047
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02855047 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations
Lead sponsor
Centre Hospitalier Universitaire de Nīmes
Phase
Observational
Overall status
Completed
Start date
July 31, 2005
Completion date
December 31, 2016
Enrollment
513 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiphospholipid syndrome